B. J Med Virol 2010;82:1835-1842.
387. Yim HJ, Yoon E, Seo YS, Kim CW, Lee CD, Park SH, et al. Adding adefovir compared with switching to entecavir in patients with lamivudine-resistant chronic hepatitis B (ACE study) - A multicenter prospective randomized study: 2 year final results. [Abstract]. Hepatology 2011;54(Suppl 1):1060-1A.
388. Suh DJ, Lee HJ, Byun KS, Cho M, Kwon YO, Chon CY, et al. A multicenter, open-labe study of efficacy and safety of peginterferon alfa-2a (40KD) in Korean patients with HBeAg-positive CHB haboring lamivduine- resistant YMDD mutants. [Abstract]. Hepatology 2008;48(Suppl 1):747A.
389. Sun J, Hou JL, Xie Q, Li XH, Zhang JM, Wang YM, et al. Randomised clinical trial: efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance. Aliment Pharmacol Ther 2011;34:424-431.
390. Villet S, Pichoud C, Villeneuve JP, Trepo C, Zoulim F. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology 2006;131:1253-1261.
391. Lampertico P, Vigano M, Manenti E, Iavarone M, Lunghi G, Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005;42:1414-1419.
392. Shin SR, Koh KC, Gwak GY, Choi MS, Lee JH, Paik SW, et al. A low viral load predicts a higher initial virologic response to adefovir in patients with Lamivudine-resistant chronic hepatitis B. Gut Liver 2010;4:530-536.
393. Gane E, Lai CL, Min A, Heathcote EJ, Poynard T, Kurdas OO, et al Adefovir salvage therapy for telbivudine treated patients from Globe with virologic breakthrough. [Abstract]. Hepatol Int 2007;1:14A.
394. Cho EY, Yim HJ, Hwang SG, Kim JH, Seo YS,Kim JH, et al. Optimal management of clevudine resistant chronic hepatitis B; A multicenter retrospective study. [Abstract]. Korean J Hepatol 2010;16(Suppl 3):S46.
395. Patterson SJ, George J, Strasser SI, Lee AU, Sievert W, Nicoll AJ, et al. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut 2011;60:247-254.
396. Reijnders JG, Deterding K, Petersen J, Zoulim F, Santantonio T, Buti M, et al. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. J Hepatol 2010;52:493-500.
397. Shim JH, Suh DJ, Kim KM, Lim YS, Lee HC, Chung YH, et al. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone. Hepatology 2009;50:1064-1071.
398. Heo NY, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir. J Hepatol 2010;53:449-454.
399. Petersen J, Lutgehetmann M, Zoulim F, Sterneck M, Janssen HL, Berg T, et al. Entecavir and tenofovir combination therpy in chronic hepatitis B: rescue therapy in patients with advanced fibrosis and multiple previous treatment failures. Results from an international multicenter cohort study. [Abstract]. Hepatoloy 2009;50(Suppl 4):496A.
400. Villet S, Ollivet A, Pichoud C, Barraud L, Villeneuve JP, Tr√©po C, et al. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol 2007;46:531-538.
401. Yatsuji H, Hiraga N, Mori N, Hatakeyama T, Tsuge M, Imamura M, et al. Successful treatment of an entecavir- resistant hepatitis B virus variant. J Med Virol 2007;79:1811-1817.
402. Kim SS, Lee DM, Jeong JY, Hong SP, Yoo WD, Kim SO, et al. Efficacy of lamivduine plus adefovir therapy or adefovir add on therapy for entecavir-resistant hepatitisn B patients. [Abstract]. Korean J Hepatol 2010;16(Suppl 3):S48.
403. Petersen J, Lutgehetmann M, Buti M, Brown A, Lampertico P, Zoulim F, et al. Treatment of multiresistant HBV patients with entecavir plus tenofovir. 2 years safety and efficacy analysis. An international multicenter cohort study. [Abstract]. J Hepatol 2011;54(Suppl 1):S299.
404. Locarnini S, Mason WS. Cellular and virological mechanisms of HBV drug resistance. J Hepatol 2006;44:422-431.
405. Locarnini S, Omata M. Molecular virology of hepatitis B virus and the development of antiviral drug resistance.

<PAGE>117